Clinical trials: B Cell
B Cell Leukemia, B Cell Lymphoma
Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma
This is a study for children who have been previously treated for Leukemia/Lymphoma. In particular, it is a study for people who have a type of Leukemia/Lymphoma that involves B cells (a type of white cell), which contain the…
- Trial name
- Pedi CART19 (NCT01626495)
- Testing
- CART-19
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Pennsylvania
Renal Failure, Chronic
Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection
Chronic transplant rejection remains the main cause of late kidney graft loss. We showed previously that patients with pretransplant CD4 helper defects and low in-vitro IL-10 responses demonstrated an extremely low risk of acute…
- Trial name
- NCT00150891
- Testing
- Kidney transplantation, cyclosporine A, tacrolimus
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- University of Giessen
Primary Mediastinal (Thymic) Large B-cell Lymphoma, Children
Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma
Addition of nivolumab (immune checkpoint inhibitor) to standard chemotherapy (DA-EPOCH-R) may improve outcome in children with primary mediastinal large B-cell lymphoma
- Conditions
- Primary Mediastinal (Thymic) Large B-cell Lymphoma, Children, Nivolumab
- Trial name
- NCT06871007
- Testing
- Nivolumab
- Where
- 2 sites in Russia
- Volunteers
- 22 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Hematologic Malignancies
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with…
- Trial name
- NCT04588922
- Testing
- SLS009, venetoclax, azacitidine
- Where
- 32 sites in United States, China
- Volunteers
- 160 people
- Sponsor
- Sellas Life Sciences Group
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
This is an exploratory, open-label, single-arm Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219C.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07507201
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Leukemia, Lymphoma
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy and total body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00028730
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
This research trial studies the use of clinical practice guidelines by pediatric oncology healthcare providers in order to identify, understand, and overcome barriers to them.
- Conditions
- Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Childhood Acute Myeloid Leukemia, Childhood Burkitt Lymphoma
- Trial name
- NCT02847130
- Testing
- Informational Intervention, Interview, Medical Chart Review
- Where
- 33 sites in United States, Puerto Rico
- Volunteers
- 530 people
- Sponsor
- Children's Oncology Group
Encephalitis, Japanese B
Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children
Japanese encephalitis (JE) is the main cause of viral encephalitis in many countries of Asia including Thailand. Estimated annual mortality ranges from10,000-15,000 deaths, while the total number of clinical cases is about…
- Trial name
- JE0153 (NCT01408537)
- Testing
- JEVAC
- Where
- Thailand
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Diffuse Large B-cell Lymphoma
Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma
The investigators perform a retrospective microarray gene expression profiling study of FFPE from a cohort of DLBCL patients with whole genome cDNA mediated Annealing Selection and Ligation (WG-DASL) assay.
- Trial name
- NCT01606605
- Where
- South Korea
- Volunteers
- 350 people
- Sponsor
- Samsung Medical Center
Sickle Cell Disease, Sickle Cell Hemoglobin C
Home-based Assessment of PRO Measures in SCD Using A Smartphone App Platform: A Feasibility Study
The overarching goal of this proposal is to identify modifiable behavioral strategies based on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) that will improve hydroxyurea (HU) adherence among…
- Conditions
- Sickle Cell Disease, Sickle Cell Hemoglobin C, Sickle Beta Zero Thalassemia, Sickle B+ Thalassemia
- Trial name
- NCT04678037
- Testing
- PROs assessment using sickle cell disease mobile app (SCD-app)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
The combination of mitoxantrone and clofarabine as reinduction therapy will be safe, well tolerated and effective in children, adolescents and young adults with poor risk refractory/relapsed acute leukemia and high grade…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoblastic Lymphoma, Diffuse Large B-cell Lymphoma
- Trial name
- MITCL (NCT01842672)
- Testing
- Clofarabine, Mitoxantrone
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- New York Medical College
B Acute Lymphoblastic Leukemia
A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia
A chimeric antigen receptor gene-modified T cells (CART: 4SCAR19)by targeted the CD19 (cluster of differentiation antigen 19), treat patients with CD19 positive malignant B cells tumor, assess treatment safety, and observe…
- Trial name
- NCT02968472
- Testing
- prophylactic 4SCAR19 cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First People's Hospital of Yunnan
Non-hodgkin Lymphoma
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05206357
- Testing
- Epcoritamab
- Where
- 41 sites in United States, Australia and 12 more
- Volunteers
- 17 people
- Sponsor
- Genmab
B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from pediatric and young adult subjects with relapsed/refractory B-cell malignancies (leukemia and…
- Conditions
- B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma
- Trial name
- NCT04088864
- Testing
- Fludarabine, Cyclophosphamide, Autologous CD22 CAR T
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Kara Lynn Davis
Diffuse Large Cell Lymphoma, Burkitt's Lymphoma
Treatment for Advanced B-Cell Lymphoma
To safely reduce the burden of therapy in children, adolescents and young adults with mature B-NHL by reducing the number of intrathecal (IT) injections by the introduction of IT Liposomal Cytarabine (L-ARA-C, [Depocyt®]) and…
- Conditions
- Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, High Grade B-cell Lymphoma
- Trial name
- REBOOT (NCT01859819)
- Testing
- Rituximab, IT Cytarabine
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- New York Medical College
Relapse/Refractory B-cell Acute Lymphoblastic Leukemia
Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
The goal of this clinical trial is to evaluate the safety and efficacy of CD19 CAR-T cells in pediatric patients of all genders, aged 2 to 18 years, with relapsing or refractory B cell acute lymphoblastic leukemia (r/r B-ALL).
- Trial name
- NCT06635330
- Testing
- anti-CD19 CAR T cell therapy
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Kara Yakhteh Tajhiz Azma Company
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL)
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia, Plasma Cell Leukemia
- Trial name
- NCT01962636
- Testing
- Fludarabine, Cyclophosphamide, Total Body Irradiation
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Large B Cell Lymphoma
Risk Adapted Therapy in Diffuse Large B Cell Lymphoma
This randomized phase II trial is studying two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell lymphoma.
- Trial name
- NCT03188198
- Testing
- rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mansoura University
B-cell Leukemia
CAR-T Immunotherapy Targeting CD19- ALL
This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients…
- Trial name
- NCT04016129
- Testing
- 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Systemic Lupus Erythematosus, Lupus Nephritis
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
- Trial name
- CALiPSO-1 (NCT06255028)
- Testing
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Century Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.